Most Read Articles
one year ago
Adjunct boceprevir is  effective for patients with human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-genotype-1 coinfection unresponsive to pegylated interferon/ribavarin (PEGIFN/RBV) therapy, as shown in a retrospective study.
2 years ago
Current management of liver abscess is by intravenous antibiotics and percutaneous treatment. The efficacy of this management was assessed in this study.
Jackey Suen, 2 years ago
Over one-third of patients with prior hepatitis B virus (HBV) exposure had HBV reactivation 2 years after haematopoietic stem cell transplantation (HSCT), according to a study by The University of Hong Kong (HKU). 
2 years ago
A randomised controlled trial demonstrated the safety of low-dose peginterferon α-2b with escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1.

AIT improves mortality, recurrence in HCC patients after curative treatment

one month ago

Adjuvant adoptive immunotherapy (AIT) for hepatocellular carcinoma (HCC) patients who have received therapy is both safe and effective for improving mortality rates and tumour recurrence, a new meta-analysis shows.

The Cochrane Library, Scopus, EMBASE and PubMed were searched for studies that investigated the effects of adjuvant AIT on HCC patients after curative treatments compared with either no interventions or control interventions. Those that considered advanced, unresectable or recurrent HCC were excluded.

The Newcastle-Ottawa and the Jadad scales were used to assess the quality of the non-randomized and observational trials, and randomized trials, respectively.

After applying the inclusion and exclusion criteria, eight studies (seven randomized controlled trials [RCT], one cohort study), corresponding to 949 treated and 912 untreated individuals, were included. Four of the RCTs had high methodological quality while three had low scores. The cohort study had a low risk of bias.

A fixed-effects model showed that, compared with curative therapies alone, adjuvant AIT was associated with improved mortality rates at 1 year (risk ratio [RR], 0.63; 95 percent CI, 0.50 to 0.78; p<0.001), 2 years (RR, 0.72; 0.63 to 0.83; p<0.001), 3 years (RR, 0.74; 0.65 to 0.83; p<0.001) and 5 years (RR, 0.88; 0.80 to 0.96; p=0.005).

Similarly, adjuvant AIT was associated with improvements in tumour recurrence rates at 1 year (RR, 0.80; 0.71 to 0.90; p=0.001), 2 years (RR, 0.80; 0.70 to 0.83; p<0.001), 3 years (RR, 0.86; 0.80 to 0.90; p<0.001) and 5 years (RR, 0.91; 0.85 to 0.97; p=0.004).

Finally, no serious adverse events or deaths were documented across the eight studies included. The most common adverse events were chills and fever. Tachycardia, itching, dizziness, myalgia, fatigue, nausea and headaches were also observed.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
one year ago
Adjunct boceprevir is  effective for patients with human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-genotype-1 coinfection unresponsive to pegylated interferon/ribavarin (PEGIFN/RBV) therapy, as shown in a retrospective study.
2 years ago
Current management of liver abscess is by intravenous antibiotics and percutaneous treatment. The efficacy of this management was assessed in this study.
Jackey Suen, 2 years ago
Over one-third of patients with prior hepatitis B virus (HBV) exposure had HBV reactivation 2 years after haematopoietic stem cell transplantation (HSCT), according to a study by The University of Hong Kong (HKU). 
2 years ago
A randomised controlled trial demonstrated the safety of low-dose peginterferon α-2b with escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1.